Monopar Therapeutics (MNPR) Retained Earnings: 2016-2020
Historic Retained Earnings for Monopar Therapeutics (MNPR) over the last 3 years, with Sep 2020 value amounting to -$30.1 million.
- Monopar Therapeutics' Retained Earnings fell 21.82% to -$30.1 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$30.1 million, marking a year-over-year decrease of 21.82%. This contributed to the annual value of -$25.9 million for FY2019, which is 19.51% down from last year.
- Monopar Therapeutics' Retained Earnings amounted to -$30.1 million in Q3 2020, which was down 5.77% from -$28.4 million recorded in Q2 2020.
- Monopar Therapeutics' Retained Earnings' 5-year high stood at -$1.9 million during Q4 2016, with a 5-year trough of -$30.1 million in Q3 2020.
- For the 3-year period, Monopar Therapeutics' Retained Earnings averaged around -$24.1 million, with its median value being -$23.9 million (2019).
- Data for Monopar Therapeutics' Retained Earnings shows a maximum YoY tumbled of 883.91% (in 2017) over the last 5 years.
- Quarterly analysis of 5 years shows Monopar Therapeutics' Retained Earnings stood at -$1.9 million in 2016, then crashed by 883.91% to -$18.4 million in 2017, then decreased by 17.52% to -$21.7 million in 2018, then declined by 19.51% to -$25.9 million in 2019, then declined by 21.82% to -$30.1 million in 2020.
- Its last three reported values are -$30.1 million in Q3 2020, -$28.4 million for Q2 2020, and -$27.0 million during Q1 2020.